|Day Low/High||20.02 / 20.76|
|52 Wk Low/High||16.56 / 62.70|
Jim Cramer lists the things we need to see before the bear backs off and the market regains its footing.
Jim Cramer weighs in on Anheuser-Busch InBev, Alteryx, Walker & Dunlop, Kratos Defense & Security, Johnson Controls, Nektar Therapeutics, Align Technology.
The most recent short interest data has been released for the 09/28/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Holzer & Holzer, LLC is investigating whether Nektar Therapeutics ("Nektar" or the "Company") (NASDAQ: NKTR) complied with the federal securities laws.
Here's what you need to know now for Tuesday, Oct. 2.
U.S. stock futures rise sharply after the U.S. reaches an agreement with Canada to revamp the North American Free Trade Agreement; Tesla soars after CEO Elon Musk settles with the SEC; California bill requires women on company boards.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AXL, BIG, DK, FOSL, NFG, NKTR, SRC, TGH, UTSI Downgrades: AIRG, AXAS, HPP, PAA, QDEL, RAD Initiations: FND, RETA, TOCA Read on to get TheStreet Quant Ratings' detailed report:
In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Nektar Therapeutics has taken over the #53 spot from Leggett & Platt, Inc. , according to ETF Channel.
Nektar Therapeutics remains the only S&P 500 company without a woman on the board, according to BoardEx, a relationship mapping service of TheStreet.
Jim Cramer says the tech titans are leading the way, but out side of the tech sector, very few stocks are following.
Jim Cramer weighs in on Hasbro, Dropbox, Carlyle Group, Corning, Banco Santander, Goldman Sachs, Edwards Lifesciences, J. Jill and more.
Every year there are 'winners' and 'losers' from the biggest confab around oncology of the year.
Nektar Therapeutics shares got destroyed on Monday. Here is why.
Jim Cramer takes a look at CVS Health, Prestige Brands, LendingTree, Valeant Pharmaceuticals, Nektar Therapeutics, Kirkland Lake and more.
Jim Cramer says Warren Buffett is the greatest investor, and his optimism has suffused trading and has been justified.
In a study of analyst recommendations at the major brokerages, for the underlying components of the S&P 500, Nektar Therapeutics has taken over the #12 spot from Thermo Fisher Scientific Inc , according to ETF Channel. Below is a chart of Nektar Therapeutics versus Thermo Fisher Scientific Inc plotting their respective rank within the S&P 500 over time (NKTR plotted in blue; TMO plotted in green): In forming the rank, the analyst opinions from the major brokerage houses were tallied, and averaged; then, the underlying components were ranked according to those averages.
These names are showing bullish and bearish technical patterns over the past week.
Could Pfizer really buy Bristol-Myers Squibb? Despite the latter's $112 billion market cap, Citi analyst Andrew Baum lays out the case for why it makes sense.
Stocks finished higher on Wednesday.
Bristol-Myers will pay $1.85 billion up front plus up to $1.78 billion in potential milestone payments to Nektar, which was reported earlier this month to be mulling options including a sale.
Bristol-Myers Squibb Company (NYSE:BMY) and Nektar Therapeutics (Nasdaq:NKTR) announced today the companies have executed a global strategic development and commercialization collaboration for Nektar's lead...
We see a notable shift away from traditional large-cap pharmaceutical stocks to more specialized niches.
It is premature to think that this market has hit a top until there is further evidence in the price action.
The New York-based firm reported net income of $5.25 per share, compared with a net loss of $1.71 per share, in the same period a year ago.
IntelliPharmaceuticals has a bio-equivalent to OxyContin, but says it is harder to tamper with. The pharma company is hoping to gain a recommendation from an FDA committee on Wednesday.
NeuroDerm, Novavax and Nektar Therapeutics were among the biotech stock movers in premarket trading on July 24.
Puma Biotechnology, Nektar Therapeutics and Paratek Pharmaceuticals were among the biotech movers in premarket trading on July 18.
NKTR-181 is the first full mu-opioid agonist molecule designed to provide potent pain relief without the high levels of euphoria that can lead to abuse and addiction with standard opioids.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.